Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ny developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... The concept of “spot reducing” areas is ... Founder of Fasciology, Ashley Black, says that even the idea ... of having to wait for the whole fat system to ... to fat cooling procedures, the only well known way ... which is a highly invasive procedure.” It is common knowledge ...
(Date:3/31/2015)...  Biotest Pharmaceuticals Corporation (BPC), a leading developer of ... of its newest plasma collection center located at 2235 ... . The over 16,000 square foot state-of-the-art facility ... th 2015 and brings the total number of ... "This facility represents another milestone in our continued efforts ...
(Date:3/31/2015)... , March 31, 2015  Sonoa Health, a health ... , has developed a world-first consumer health portal, Health&, ... prescriptions, wearable devices and more. Today, the ... as its CEO, who brings to the table more ... which has included working closely with the biggest names ...
(Date:3/31/2015)... -- University of Illinois, Swanlund Chair ... session address on Monday, May 18 at the ... off a week of more than 160 technical sessions ... and microwave technologies with health. Dr. Rogers, ... for the Skin," will focus on the experimental and ...
Breaking Biology Technology:Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 2Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 3Biotest Pharmaceuticals Corporation Announces the Opening of its Newest Plasma Collection Facility in Conway, Arkansas 2Investment Banker Appointed CEO of Australian Health Tech Start-Up 2Investment Banker Appointed CEO of Australian Health Tech Start-Up 3Health and Engineering Converge at the 2015 International Microwave Symposium 2Health and Engineering Converge at the 2015 International Microwave Symposium 3
... chain technology provider, reported Friday that its ... a George-based division of Cooper Industries, to ... , ,The lighting manufacturer is replacing its ... and workforce performance management applications. , ,RedPrairie's ...
... A new report of health care sector venture capital shows ... 2005, but its position could shoot up as the state's investment ... by BioEnterprise , a business formation and management counseling service ... we initiated this report last quarter is we felt like a ...
... -- Cummins, Inc. of Columbus, Ind., ... part of its global supply chain strategy initiative, ... use Waukesha-based RedPrairie's warehouse management solution across its ... divisions will implement RedPrairie's workforce performance management, slotting, ...
Cached Biology Technology:Wisconsin ranks low in mid-year health care capital investment report 2Wisconsin ranks low in mid-year health care capital investment report 3
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... The DHS Science and Technology Directorate,s Fifth Annual ... DC Renaissance Hotel March 30-April 1 2011. ... is well attended by university scientists, government officials ... scientists working on DHS high-priority research areas with ...
... (February 24, 2011) A research team, led ... shed new light on the problem of insulin resistance, and ... holds therapeutic promise for reducing the severity of type 2 ... an immune system signaling molecule, in triggering inflammation, which significantly ...
... of Tennessee, Knoxville, researchers has conducted the first-ever genetic ... the genome of the micro-organism responsible for the Eastern ... scallop industries of New York and New Jersey in ... waters off North America and South Africa. The tides ...
Cached Biology News:DHS Science and Technology Directorate's science conference: 'Catastrophes and Complex Systems' 2DHS Science and Technology Directorate's science conference: 'Catastrophes and Complex Systems' 3DHS Science and Technology Directorate's science conference: 'Catastrophes and Complex Systems' 4La Jolla Institute-led team illuminates cell pathway key to insulin resistance in Type 2 diabetes 2La Jolla Institute-led team illuminates cell pathway key to insulin resistance in Type 2 diabetes 3UT researchers crack code to harmful brown tides 2
...
... light scattering detector for ambient HPLC. ... processing hardware for two external devices ... Also contains an analog output from ... strip chart recorders. Includes an input ...
...
MAb to Verotoxin II (SLT-2a) Verotoxin II (Shiga-like) A subunit (SLT-2a)...
Biology Products: